What If Depression Treatment Is Not Working? Next Steps
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
If your depression treatment is not working, the next step is a structured review with your clinician. Check how long the treatment has been used, whether it has been delivered at an adequate dose or intensity, whether there has been any partial improvement, whether side effects have prevented consistent treatment, and whether the diagnosis or other health conditions need reconsideration. Your options may include adjusting the existing plan, changing treatment, adding psychotherapy or medication, or requesting specialist evaluation. A disappointing first response does not establish treatment-resistant depression. NICE guidance on further-line care and the CANMAT guidelines support a collaborative, sequential approach.
This guide focuses on the practical question 'What should I do when depression treatment is not helping?' It is distinct from the broader review of depression treatment options and from the specialized clinical definition of treatment-resistant depression. It covers treatment with antidepressants, psychotherapy, or both. The examples primarily concern adults; children, adolescents, pregnancy, bipolar illness, and urgent psychiatric situations require their own clinical pathways.
I. The Essential Next Steps
Arrange a follow-up appointment with the clinician responsible for your care, preferably before changing treatment on your own. Explain what has changed since treatment began, including mood, pleasure, sleep, energy, concentration, daily functioning, anxiety, and any adverse effects. If you have been taking medication, bring the name, prescribed amount, start date, recent changes, missed doses, other medicines, and supplements. If you have been attending therapy, describe its goals, how many sessions you have attended, what you have practiced between sessions, and which obstacles are still present.
Ask the clinician to answer four questions in order: Was this a sufficient treatment trial? Is the diagnosis still the best explanation? Is there a safety issue or medical complication requiring immediate care? Which adjustment offers the best balance of likely benefit, burden, adverse effects, access, and your preferences? The VA/DoD guideline and NICE both organize next-step decisions around reassessment rather than automatic escalation.
Seek urgent assessment instead of waiting for a routine review if you have imminent intent to harm yourself, cannot maintain basic safety, experience hallucinations or delusions with dangerous consequences, develop severe agitation or signs of mania, or become unable to eat, drink, or care for essential needs. Contact local emergency services or go to the nearest emergency department. In the United States, call or text 988 for crisis support; elsewhere use your local crisis service. A person facing immediate danger needs emergency assistance. NIMH warning signs and crisis guidance.
II. What Does 'Treatment Is Not Working' Actually Mean?
1. No response, partial response, and remission
No response means symptoms have changed little, or improvement is too small to be clinically meaningful. Partial response means some symptoms or everyday abilities have improved, while clinically important symptoms remain. Response is usually a substantial reduction in symptom burden; remission means symptoms have fallen below an agreed clinical threshold and meaningful functioning has recovered. A person may feel less tearful yet remain unable to work, sleep, connect with others, or experience pleasure. These patterns call for different next decisions, and none can be established by a single online score.
A relapse is the return of clinically significant symptoms before sustained recovery from an episode; recurrence usually denotes a new depressive episode after recovery. Persistent symptoms despite a treatment trial are a different problem from renewed symptoms after an effective course. When discussing your experience, identify whether treatment has never helped, helped somewhat, caused intolerable adverse effects, or initially helped but later stopped providing sufficient relief. Longitudinal symptom and functioning records can clarify these distinctions. CANMAT.
2. One unsuccessful treatment is not the same as treatment resistance
Treatment-resistant depression (TRD) is commonly operationalized as failure to achieve satisfactory improvement after at least two adequate antidepressant treatments within the current depressive episode, although research definitions and clinical thresholds vary. Inadequate treatment duration, missed doses, intolerable side effects, an inaccurate diagnosis, and significant comorbidity can make an apparent failure difficult to classify. Nonresponse to a first medication or first course of psychotherapy should prompt careful follow-up; it does not by itself justify a TRD label. NICE and CANMAT.
The term 'difficult-to-treat depression' is sometimes used in specialist care to acknowledge ongoing illness, treatment burden, and complex individual goals after several interventions. It is a clinical management concept rather than permission to declare a person beyond help. Even after multiple disappointments, the next plan can target meaningful reductions in symptoms, better function, tolerability, quality of life, or maintenance of gains. Specialist assessment becomes more useful as the course becomes more complicated. CANMAT.
III. How Long Should Treatment Be Given Before It Is Reassessed?
1. Antidepressants
Antidepressant effects evolve over weeks. Early changes in sleep, anxiety, energy, or appetite may differ from changes in depressed mood or interest. A short period without noticeable improvement is not sufficient evidence that a prescription cannot help, while persistent worsening or unacceptable adverse effects warrant earlier contact. NICE recommends discussing lack of response after four weeks of antidepressant medication at a recognized therapeutic dose; it also recommends that clinicians review medication use, barriers and the diagnosis before choosing further-line treatment. NICE further-line recommendations.
A useful question at the appointment is: 'Have I had enough time at a suitable dose to judge this trial?' The answer depends on the medicine, tolerability, starting dose, interruptions, symptom severity, and the clinician's observation. Some people improve after a longer monitored trial, and some benefit from an earlier change because severe symptoms, adverse effects, or deteriorating functioning make continued waiting less appropriate. Do not increase a dose or stop medication independently to test whether it works. NICE; CANMAT.
2. Psychotherapy
Psychotherapy is a structured course whose pace depends on the modality, therapeutic agreement, symptom complexity, and frequency of sessions. NICE recommends a treatment review if psychological therapy or combined treatment has yielded no response after about four to six weeks. That is a decision point for discussing progress, engagement, barriers, and potential adjustments; it is not a universal deadline by which every patient should have recovered. The clinician and therapist should evaluate whether the treatment delivered matches the intended therapeutic method and target problems. NICE.
At the review, ask what changes you and the therapist expected, how progress is being measured, how each session relates to a treatment formulation, and what adaptations could address obstacles. If you feel misunderstood, emotionally unsafe, or unable to discuss sensitive problems, bring this into the conversation. Therapeutic collaboration, accessibility, family circumstances, financial strain, and competing obligations can influence what is realistically possible. Changing therapist or modality may be reasonable after a thoughtful review, particularly when a clearly defined method has not engaged the core symptoms.
3. Combined treatment
If you are taking an antidepressant and attending psychotherapy, review both components separately and together. Medication may have reduced some symptoms while therapy has not yet helped behavior or functioning, or the reverse may be true. Assess whether each component has been given a reasonable chance and whether coordination between professionals is adequate. NICE includes combined treatment and modifications to either component among legitimate further-line choices. NICE.
IV. Reconstruct the Actual Treatment Trial
A clinician cannot interpret treatment failure accurately from a drug name and a statement that 'it didn't work.' The review needs to establish what was tried, when, for how long, at what intensity, with what adherence, at what cost, and with what effect. This is a clinical reconstruction, not a test of the patient's effort or motivation. Side effects, cost, stigma, transportation, scheduling, executive difficulties, unstable housing, and misunderstanding instructions all affect feasibility and should be treated as practical problems to solve. NICE.
1. Medication history
For each antidepressant, note approximate start and end dates, dose changes as prescribed, missed doses, whether it was taken daily or intermittently, main adverse effects, other prescribed or recreational substances, and reasons for stopping. Record any genuine benefit, even if small. Switching a medicine after only brief low-dose exposure for tolerability is different from switching after an adequate therapeutic trial with no improvement. Pharmacokinetic interactions and some medical conditions can also affect exposure and tolerability. Ask a clinician or pharmacist to review interactions rather than attempting to alter your regimen yourself. CANMAT.
2. Psychotherapy history
For psychotherapy, note modality where known, number and spacing of sessions, the target symptoms, homework or behavioral practices offered, session attendance, and the specific obstacles that blocked progress. A completed course of structured behavioral activation differs from intermittent supportive conversations. A trial that was inaccessible, culturally mismatched, repeatedly interrupted, or impossible to participate in requires a different interpretation from a well-delivered intervention that brought little benefit. Both situations call for a better plan.
3. What improved and what remains impaired?
Measure everyday outcomes alongside symptoms: getting out of bed, sustaining attention, attending school or work, preparing meals, reconnecting with people, and experiencing enjoyment. If sleep improves but hopelessness intensifies, progress is mixed and safety matters. If work attendance resumes but anhedonia and exhaustion persist, remission has not necessarily occurred. Standardized symptom measures can help document change when interpreted with a clinical interview; they are monitoring instruments, not stand-alone diagnostic or prescribing tools. VA/DoD.
V. Reassess the Diagnosis and Other Explanations
1. Review the depressive episode and differential diagnoses
Depression is a clinical syndrome assessed through symptom history, duration, severity, impairment, course, contextual information, and the examination of alternative causes. Clinicians may revisit major depressive disorder, persistent depressive disorder, anxiety disorders, trauma-related conditions, substance-related disorders, psychotic depression, adjustment disorder, and medical or medication-induced depressive symptoms. A patient whose initial diagnosis was uncertain may benefit from a comprehensive depression clinical evaluation rather than another automatic prescription. NIMH depression guidance; NICE.
2. Ask specifically about hypomania, mania, and mixed symptoms
An unrecognized history of hypomania or mania can change both the diagnosis and the safety of the proposed treatment. Tell the clinician about periods of markedly reduced need for sleep together with unusually elevated or irritable mood, increased energy, pressured speech, impulsive spending, inflated confidence, racing thoughts, or risky behavior. Also disclose mixed symptoms, agitation, or major sleep reduction emerging after an antidepressant change. Bipolar depression is managed differently from unipolar depression, and antidepressant monotherapy may be inappropriate in some bipolar presentations. NIMH bipolar disorder; CANMAT.
3. Medical conditions, medicines, and substance use
A reassessment may consider thyroid disease, anemia or other medical causes of fatigue, sleep disorders, chronic pain, neurological disease, medication effects, alcohol or substance use, and other health conditions when the history or examination suggests them. The appropriate laboratory tests depend on clinical findings; an indiscriminate panel of 'depression blood tests' is not a substitute for evaluation. Review all drugs and supplements, including recent changes, with the treating clinician. Treating a coexisting condition can improve function and make an evidence-based depression plan more effective. CANMAT; NICE.
4. Stress, losses, and psychosocial pressures
Persistent financial insecurity, unstable housing, isolation, intimate-partner harm, caregiving demands, chronic discrimination, bereavement, and work stress may maintain distress or obstruct treatment engagement. Depression may coexist with these pressures; recognizing them helps clinicians choose support that is attainable. A treatment review should include practical and social circumstances alongside symptom counts. Care coordination, benefits advice, accessibility supports, family work, or referral to community services may be as important to implementation as the next clinical modality. NICE assessment recommendations.
VI. What Can a Clinician Change After an Inadequate Response?
Several evidence-supported strategies are available. Their ordering depends on whether the first treatment produced no response or a partial response, whether the patient can tolerate it, how severe the depression is, what has already been tried, and what the person prefers. The decision should be explicit: continue and monitor, optimize, switch, combine, augment, or refer for specialist interventions. Each pathway has a different benefit-and-harm profile. CANMAT; VA/DoD.
1. Optimize a treatment that is helping somewhat
When a treatment produces a meaningful but incomplete benefit and is tolerable, a clinician may recommend more time, dose optimization within approved and individualized limits, greater treatment intensity, or a structured psychological addition. Higher doses are not automatically more effective and may increase adverse effects. If dose changes are considered, ask what additional improvement is expected, what symptoms will be monitored, and when the decision will be revisited. Optimization is a clinical decision, not a universal instruction to take more medication. CANMAT.
2. Switch antidepressants after nonresponse or poor tolerability
Switching can be appropriate when an adequate antidepressant trial has produced little benefit or important adverse effects. Options can include another drug within the same class or a drug with a different profile. The STAR*D study found that several second-step switches could produce remission after an unsuccessful SSRI trial, without one evaluated switch showing clear superiority. This study established useful possibilities, not a personalized prediction for any patient. A switch requires an individualized plan for tapering, interactions, washout where necessary, and follow-up. Rush and colleagues, STAR*D; CANMAT.
Antidepressant discontinuation effects can include dizziness, flu-like sensations, insomnia, anxiety, and unusual sensory sensations; severity and duration vary by drug, dose, history, and individual susceptibility. Abrupt stopping can create new symptoms that resemble depression or complicate assessment. Certain combinations and transitions also raise interaction risks, including serotonin toxicity. Ask the prescriber for a clear transition schedule and what to do if symptoms appear. The plan is especially important with medicines requiring prolonged washout intervals. NICE stopping guidance; CANMAT.
3. Add or change psychotherapy
Evidence-based depression-focused options include cognitive behavioral therapy, behavioral activation, interpersonal psychotherapy, and other structured approaches appropriate to the person's circumstances. Therapy may help when the medication response is incomplete, and medication may be useful when a properly delivered psychotherapy has not achieved sufficient recovery. A clinician may also suggest a different modality if the original approach has not fit the presenting mechanisms or practical realities. For a full comparison of these methods, see the depression treatment overview. NICE; VA/DoD.
When therapy has stalled, the next step may involve clearer shared goals, measurement of change, treatment for complicating anxiety or trauma symptoms, closer session frequency, a different evidence-based therapist, or a change from a nonstructured approach to a manualized intervention. The choice should depend on a new formulation of the difficulties rather than a reflexive judgment that therapy 'does not work' for a person. With severe, recurrent, or chronic symptoms, coordinated care across prescriber and therapist is especially useful.
4. Augment an antidepressant under medical supervision
Augmentation means adding another treatment while continuing one that provides some benefit. Depending on context, specialists may consider certain second-generation antipsychotics, lithium, another antidepressant, or other evidence-based strategies. Choice depends on diagnosis, previous response, drug interactions, pregnancy considerations, physical health, and patient preference. The STAR*D program provides an early example of additional medication leading to remission for some patients who had not remitted on an SSRI. Trivedi and colleagues; CANMAT.
Augmenting agents carry substantial and different monitoring needs. Some antipsychotic medicines may cause weight gain, metabolic changes, restlessness or movement effects. Lithium may require serum levels and monitoring of thyroid and kidney function. Clinicians must explain potential burdens and develop a follow-up schedule. Combining serotonergic drugs without professional management can be dangerous. More medication is never automatically synonymous with better care; augmentation is most sensible when potential benefit justifies its individualized risks. NIMH medications; NICE.
5. Consider repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) delivers targeted magnetic pulses through equipment placed against the scalp. It is a clinician-delivered, noninvasive option for selected patients with depression after medication nonresponse or intolerance. Treatments are usually scheduled repeatedly over a course, and access, time commitments, headaches, and device-specific eligibility should be discussed. FDA-cleared indications and protocols depend on the device. The VA/DoD guideline suggests rTMS after at least two adequate pharmacologic trials with partial or no response; clinical eligibility is individualized. VA/DoD; NIMH brain stimulation review.
6. Discuss electroconvulsive therapy when severity or urgency warrants it
Electroconvulsive therapy (ECT) is performed in a medical setting under anesthesia and induces a controlled seizure using electrical stimulation. It can be considered for severe depression when prior treatments have not worked, when the individual previously benefited and prefers it, or when rapid improvement is necessary because depression is life-threatening—for example, an inability to eat or drink. Memory and other cognitive effects, anesthesia risk, medical conditions, consent, and individualized expected benefits require an explicit specialist discussion. NICE ECT recommendations; NIMH brain stimulation review.
7. Understand esketamine and ketamine accurately
In the United States, intranasal esketamine (Spravato) is FDA-approved for treatment-resistant depression in adults, either alone or alongside an oral antidepressant under the January 2025 labeling. It is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior in combination with an oral antidepressant. Importantly, its effectiveness in preventing suicide has not been established. Its restricted REMS program requires supervised administration and monitoring because sedation, dissociation, respiratory depression, abuse or misuse, and blood-pressure effects pose clinically important risks. FDA prescribing information, January 2025.
Intravenous racemic ketamine used for depression is an off-label intervention in the United States; ketamine itself is not FDA-approved for psychiatric disorders. Compounded ketamine products are also not FDA-approved, and their safety, efficacy, and quality are not assessed by FDA through normal drug approval. Home-delivered products advertised as substitutes for specialist care should therefore be evaluated with particular caution. Availability and regulation vary by country. A specialist discussion should address evidence, clinical monitoring, cost, recurrence of symptoms, and alternatives, not rely on promotional promises. FDA compounding safety alerts; CANMAT.
VII. If Medication Helped at First and Then Stopped Helping
A decline after initial improvement requires a timeline. Was the person in full remission, or were residual symptoms already present? Did medication adherence change? Was another medicine added? Did sleep, alcohol use, physical illness, or major life stress change? Is the person experiencing relapse during treatment, recurrence after recovery, or discontinuation effects after reducing a drug? These scenarios call for different actions. A prescriber may revisit the original response, check adherence and interactions, review diagnosis and risk, and then discuss dose adjustment, switching, augmentation, or psychotherapy. NICE relapse and further-line care.
The popular label 'antidepressant poop-out' describes a perceived loss of drug effect, sometimes called tachyphylaxis in the literature. It is not a stand-alone depressive disorder diagnosis. The phrase does not establish why symptoms returned. Before assuming a drug has biologically stopped working, a clinical review should investigate residual disease, stressors, interrupted treatment, adverse effects, and differential diagnoses. Reassessment should remain grounded in the observed course and the person's functioning.
VIII. Situations Requiring a Different Pathway
1. Children and adolescents
Young people's depression treatment requires developmentally appropriate assessment, caregiver involvement when appropriate, safety monitoring, and specialist attention to medication and psychotherapy evidence. Emerging suicidal thoughts, unusual agitation, or behavioral activation after starting or changing an antidepressant deserve prompt review. Adult sequencing recommendations cannot simply be transferred to minors. A pediatric or adolescent mental health clinician should guide medication changes and the choice of psychotherapy. The FDA boxed warnings for antidepressants and the NIMH medication overview highlight age-related monitoring considerations.
2. Pregnancy, postpartum, and reproductive contexts
When pregnancy is possible or ongoing, or depression arises around childbirth, risks and benefits of treatment must be considered alongside maternal and infant health. Suddenly stopping effective medication because of pregnancy fears may introduce its own risks. Consultation among the patient, mental health prescriber, and relevant reproductive health clinician is appropriate. Perinatal and postpartum depression belong to a specialized clinical pathway beyond the scope of this general article.
3. Psychosis, severe self-neglect, or rapid deterioration
Delusions, hallucinations, profound psychomotor changes, inability to maintain nutrition or hydration, or severe self-neglect demand prompt specialist assessment. Depression with psychotic features may require antidepressant plus antipsychotic treatment, ECT, or other specialist interventions according to severity and response. A routine 'try another antidepressant next month' approach is inappropriate when urgent care is indicated. NICE psychotic depression and ECT guidance.
4. Co-occurring anxiety, substance use, or chronic disease
Co-occurring problems can complicate progress, but they do not mean a person cannot improve. The care plan should identify which problems are driving distress, how interventions interact, and whether separate or integrated treatment is necessary. For example, anxiety and depression commonly co-occur, and persistent avoidance, insomnia, panic, or excessive worry may require explicit attention. Substance use or chronic medical symptoms may require coordination with other specialties. NICE; CANMAT.
IX. How to Prepare for a Productive Treatment Review
Write a one-page account of the treatment course: diagnosis or working diagnosis, dates and dosages, therapy sessions and methods, a short symptom timeline, daily functioning, benefits, side effects, missed treatment, and relevant medical changes. Include what matters most to you: improved concentration, connection with family, relief from suicidal thinking, a safe medication change, returning to studies, or simply enough energy to meet daily needs. Bring a trusted supporter if you want and if it helps you communicate. VA/DoD patient tools.
Ask: 'What specifically counts as adequate exposure to this treatment? Are there signs of partial benefit? Could we have missed bipolar symptoms, another diagnosis, or a medical contributor? Which options have the best evidence after my particular prior trial? What are the side effects and monitoring requirements? When will we review the next step? At what point should we involve a psychiatrist or specialist service?' Shared decisions become much more useful when the clinician and patient agree on a review date and measurable goals. CANMAT.
A reasonable follow-up plan identifies one or more target symptoms and functional outcomes, the intervention chosen, a timeline appropriate to it, anticipated adverse effects, what requires early contact, and a contingency if improvement remains limited. The plan should also state who coordinates care and how information moves between prescriber and therapist. Regular monitoring can identify improvement, worsening, adherence barriers, or adverse effects before another prolonged trial has passed. NICE; VA/DoD.
X. Common Mistakes That Can Delay Better Care
One mistake is remaining indefinitely on a treatment that is clearly ineffective without a scheduled review. Another is declaring a treatment a failure before it has been administered adequately. Sudden medication discontinuation, unsupervised dose changes, indiscriminate supplement combinations, and reliance on online ratings of a medication can introduce preventable risk. Equally important is the assumption that persistent symptoms must always be solved by increasing a prescription while the diagnosis, psychotherapy quality, physical health, and life circumstances go unexamined. NICE; CANMAT.
Another avoidable mistake is interpreting nonresponse as a personal failure. Depression outcome varies because treatment effects, illness history, comorbidities, clinical fit, biological and social factors, and practical access vary. The evidence supports multiple possible next steps, but it does not guarantee that any one will help a particular person. A structured review replaces guesswork with a record of decisions and consequences. That is also why specialists may become more valuable after complicated or repeated inadequate trials. VA/DoD.
XI. Frequently Asked Questions
Should I wait longer if my antidepressant is not helping?
Ask your prescriber for a review of the duration, therapeutic dose, adherence, adverse effects and symptom trajectory. NICE identifies four weeks at a recognized therapeutic dose without response as a point for discussion; some situations justify earlier reassessment, and some partially improving patients may benefit from further monitored time. There is no universal instruction to stop or increase medication after a fixed number of days. NICE.
Does one antidepressant failure mean I have treatment-resistant depression?
No. TRD commonly refers to inadequate response after at least two adequate antidepressant trials in a depressive episode, with meaningful variation among clinical definitions. A single unsuccessful or poorly tolerated drug trial is a reason to review the treatment plan. CANMAT.
Is switching better than adding a second treatment?
Neither is always better. Switching may be attractive after no response or problematic side effects. Augmentation or combined care may make sense after partial improvement with good tolerability. Direct comparative evidence varies, and augmentation often increases treatment burden and monitoring requirements. The clinician should connect the decision to your previous response, diagnosis, risks, and preferences. CANMAT; STAR*D.
Can psychotherapy work after a medication does not?
Yes. Evidence-based psychological treatment can be offered after an insufficient medication response, by itself or together with medication depending on severity and preferences. The clinician should choose a depression-specific approach and review whether it is accessible, acceptable and adequately delivered. NICE; VA/DoD.
What if therapy has not helped after several sessions?
Discuss whether the course has reached a meaningful review point, what specific goals it addresses, whether barriers or mismatches are interfering, and whether treatment should be adapted, intensified, or changed. NICE calls for review of no response after roughly four to six weeks of psychotherapy, not automatic abandonment of therapy. NICE.
Can I stop an antidepressant that makes me feel worse?
Contact the prescriber promptly, especially with severe agitation, unusual behavior, marked deterioration or suicidal thoughts. Immediate danger requires urgent care. Discontinuation and switching usually need a clinician-designed schedule to manage withdrawal, relapse and interactions. Avoid making a sudden independent change except when emergency professionals direct you to do so. NICE.
When should I ask for a second opinion or specialist referral?
A second opinion is reasonable when the diagnosis remains uncertain, multiple adequate treatments have provided limited benefit, side effects are difficult to manage, bipolar or psychotic symptoms may be present, medical comorbidity is complex, or advanced interventions are being considered. You can request a psychiatrist or multidisciplinary specialist review while maintaining continuity with existing clinicians. VA/DoD; CANMAT.
Will depression always return after treatment starts working?
No. Course varies. Some people experience one episode, while others have persistent or recurrent illness. Residual symptoms, previous episodes and other clinical factors influence individualized prevention plans. Once improvement occurs, discuss how long to maintain effective treatment, whether relapse-prevention psychotherapy is useful, and what early changes should prompt contact. NICE.
Do supplements, genetic tests, or consumer AI chatbots identify the right next treatment?
Evidence for many commercial supplements and direct-to-consumer 'personalized depression fixes' is limited or inconsistent. Pharmacogenetic testing may sometimes help explain unusual adverse effects or medication metabolism, but it does not reliably predict the uniquely best antidepressant for every patient. General-purpose AI chatbots and consumer wellness tools should not replace a clinical reassessment or emergency evaluation. Discuss any supplement or test with the clinician before making changes. CANMAT; VA/DoD.
XII. The Practical Conclusion
When depression treatment is not working, the right response is to make the care plan more specific. Establish the real pattern of response, confirm that treatment was adequately tried, revisit the diagnosis and coexisting conditions, assess urgent safety needs, and choose an evidence-based next step with explicit monitoring. Different people may benefit from optimization, switching medication, adding or adapting psychotherapy, supervised augmentation, or specialist procedures. Continuing care with a clear sequence and measurable goals gives each new decision a meaningful basis. NICE; CANMAT; VA/DoD.
Related Articles
Depression Treatment: Therapy, Medication, and Other Options — overview of condition-specific treatments, comparative options and shared decisions.
Depression Diagnosis: What a Clinical Evaluation Includes — understanding why symptoms, diagnostic history, and other conditions deserve review.
Anxiety and Depression: Why They Commonly Co-Occur — a cross-cluster guide to overlapping symptoms and care considerations.
References
Canadian Network for Mood and Anxiety Treatments (CANMAT). (2024). Canadian Network for Mood and Anxiety Treatments 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry. DOI: 10.1177/07067437241245384.
National Institute for Health and Care Excellence (NICE). (2022; reviewed 2026). Depression in adults: Treatment and management. NICE guideline NG222. Clinical recommendations.
National Institute of Mental Health (NIMH). Bipolar disorder. Official clinical information.
National Institute of Mental Health (NIMH). Brain stimulation therapies. Official treatment review.
National Institute of Mental Health (NIMH). Depression. Official patient information.
National Institute of Mental Health (NIMH). Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Level 2 results. Official research summary.
National Institute of Mental Health (NIMH). (2025). Warning signs of suicide. Official crisis guidance.
Rush, A. J., et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231–1242. DOI: 10.1056/NEJMoa052963.
Trivedi, M. H., et al. (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine, 354, 1243–1252. DOI: 10.1056/NEJMoa052964.
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder. Guideline and clinician materials.
U.S. Food and Drug Administration (FDA). Compounding risk alerts: Ketamine products and psychiatric disorders. FDA safety resources.
U.S. Food and Drug Administration (FDA). (2025). Spravato (esketamine) nasal spray: Prescribing information (revised January 2025). Official label.